[1] Burnett A, Wetzler M, Löwenberg B.Therapeutic advances in acute myeloid leukemia[J]. J Clin Oncol,2011, 29(5):487-494.
[2] Stein EM.Molecularly targeted therapies for acute myeloid leukemia[J]. Hematology Am Soc Hematol Educ Program,2015:579-583.
[3] Kelly LM, Gilliland DG.Genetics of myeloid leukemias[J]. Annu Rev Genomics Hum Genet,2002,3:179-198.
[4] Shen H, Laird PW.Interplay between the cancer genome and epigenome[J]. Cell,2013,153(1):38-55.
[5] Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia[J]. N Engl J Med,2013, 368(22):2059-2074.
[6] Figueroa ME, Lugthart S, Li Y, et al.DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia[J]. Cancer Cell,2010,17(1): 13-27.
[7] Shen Y, Zhu YM, Fan X, et al.Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia[J]. Blood,2011,118(20):5593-5603.
[8] Bullinger L, Ehrich M, Döhner K, et al.Quantitative DNA methylation predicts survival in adult acute myeloid leukemia[J]. Blood,2010,115(3):636-642.
[9] Rice KL, Hormaeche I, Licht JD.Epigenetic regulation of normal and malignant hematopoiesis[J]. Oncogene,2007, 26(47):6697-6714.
[10] Yang L, Rau R, Goodell MA.DNMT3A in haematological malignancies[J]. Nat Rev Cancer,2015,15(3):152-165.
[11] Challen GA, Sun D, Jeong M,et al.Dnmt3a is essential for hematopoietic stem cell differentiation[J]. Nat Genet,2011,44(1):23-31.
[12] Mayle A, Yang L, Rodriguez B, et al.Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation[J]. Blood,2015,125(4):629-638.
[13] Shlush LI, Zandi S, Mitchell A, et al.Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia[J]. Nature,2014,506(7488):328-333.
[14] Ley TJ, Ding L, Walter MJ, et al.DNMT3A mutations in acute myeloid leukemia[J]. N Engl J Med, 2010,363(25):2424-2433.
[15] Yan XJ, Xu J, Gu ZH, et al.Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia[J]. Nat Genet,2011, 43(4):309-315.
[16] Hou HA, Kuo YY, Liu CY, et al.DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications[J]. Blood,2012,119(2):559-568.
[17] Russler-Germain DA, Spencer DH, Young MA, et al.The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers[J]. Cancer Cell,2014,25(4):442-454.
[18] Holz-Schietinger C, Matje DM, Reich NO.Mutations in DNA methyltransferase(DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation[J]. J Biol Chem,2012,287(37):30941-30951.
[19] Schoch C, Schnittger S, Klaus M, et al.AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases[J]. Blood,2003,102(7):2395-2402.
[20] Zhao X, Chen A, Yan X, et al.Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal[J]. Blood,2014,123(211):1729-1738.
[21] Weidner CI, Walenda T, Lin Q, et al.Hematopoietic stem and progenitor cells acquire distinct DNA-hypermethylation during in vitro culture[J]. Sci Rep,2013, 3:3372.
[22] Zhou J, Wu J, Li B, et al.PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway[J]. Leukemia,2014,28(7):1436-1448.
[23] Papaemmanuil E, Gerstung M, Bullinger L, et al.Genomic classification and prognosis in acute myeloid Leukemia[J]. N Engl J Med,2016,374(23):2209-2221.
[24] Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
[25] Friedman AD.Transcriptional control of granulocyte and monocyte development[J]. Oncogene,2007,26(47):6816-6828.
[26] 沈志祥. 我国急性髓系白血病(非M3)的诊治现状[J]. 诊断学理论与实践,2017,16(1):1-3.
